Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Archives of Virology
Erschienen in: Archives of Virology 11/2019

09.08.2019 | Review

Expression and detection of anti-HBs antibodies after hepatitis B virus infection or vaccination in the context of protective immunity

verfasst von: Robério Amorim de Almeida Pondé

Erschienen in: Archives of Virology | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Abstract

Anti-HBs antibodies develop after natural infection with hepatitis B virus (HBV) or vaccination against this virus, as a result of activation of the human immune system by the HBV surface antigen (HBsAg). Anti-HBs-positive individuals are immunologically competent against HBV infection. This immunity is determined by the antibody levels in the bloodstream after resolution of natural infection or after vaccination. Anti-HBs antibody levels have been observed to decrease to below the protective level years after natural infection or vaccination, and there is reason to doubt that protective immunity to HBV is maintained after that. Factors that affect the maintenance of the anti-HBs antibody level in the bloodstream have been reported. Maintenance of immunity to HBV has been reported in anti-HBs negative individuals and those with detectable but low levels after natural infection or after vaccination. On the other hand, detection of anti-HBs antibodies without protective activity has also been observed. The presence or absence of anti-HBs antibodies in the context of HBV immunity has been the subject of extensive discussion and clinical, laboratory and epidemiological interest. These three scenarios of the anti-HBs response are discussed in this review article.
Literatur
1.
2.
3.
Habib S, Shaikh O (2007) Hepatitis B immune globulin. Drugs Today (Barc). 43(6):379–394PubMed
4.
5.
Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP (2006) Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 28:112–125PubMed
6.
Greub G, Frei P (2001) Presence of low levels of anti-HBs antibody in so-called ‘anti-HBc alone’ subjects. Liver 21:380–383PubMed
7.
8.
Fisman DN, Agrawal D, Leder K (2002) The effect of age on immunologic response to recombinant hepatitis B vaccine: a meta-analysis. Clin Infect Dis 35:1368–1375PubMed
9.
Hernandez-Bernal F, Aguilar-Betancourt A, Aljovin V et al (2011) Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults. Hum Vaccin 7:1026–1036PubMed
10.
Kamath GR, Shah DP, Hwang LY (2014) Immune response to hepatitis B vaccination in drug using populations: a systematic review and meta-regression analysis. Vaccine 32:2265–2274PubMed
11.
Kubba AK, Taylor P, Graneek B, Strobel S (2003) Non-responders to hepatitis B vaccination: a review. Commun Dis Public Health 6:106–112PubMed
12.
Fonseca MO, Pang LW, de Paula Cavalheiro N, Barone AA (2005) Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 23:2902–2908PubMed
13.
14.
15.
Miyake T, Akbar SM, Yoshida O, Chen S, Hiasa Y, Matsuura B, Abe M, Onji M (2010) Impaired dendritic cell functions disrupt antigen-specific adaptive immune responses in mice with nonalcoholic fatty liver disease. J Gastroenterol 45:859–867PubMed
16.
Park HL, Shim SH, Lee EY, Cho W, Park S, Jeon HJ, Ahn SY, Kim H, Nam JH (2014) Obesity-induced chronic inflammation is associated with the reduced efficacy of influenza vaccine. Hum Vaccin Immunother 10:1181–1186PubMedPubMedCentral
17.
Frasca D, Diaz A, Romero M, Mendez NV, Landin AM, Ryan JG, Blomberg BB (2013) Young and elderly patients with type 2 diabetes have optimal B cell responses to the seasonal influenza vaccine. Vaccine 31(35):3603–3610PubMedPubMedCentral
18.
19.
Rahman F, Dahmen A, Herzog-Hauff S, Bocher W, Gallep P, Lohr H (2000) Cellular and humoral immune responses induced by intradermal or intramuscular vaccination with the major hepatitis B surface antigen. Hepatology 31:521–527PubMed
20.
Milich DR, Leroux-Roels GG (2003) Immunogenetics of the response to HBsAg vaccination. Autoimmun Rev 2(5):248–257PubMed
21.
Rehermann B, Nascimbeni M (2005) Immunology of hepatitis B vírus and hepatitis C virus infection. Nat Rev Immunol 5:215–229PubMed
22.
Abbas AK, Lichtman AH, Pillai S (2007) Cellular and molecular immunology, 6th ed, Editora Saunders, ‎Philadelphia
23.
Penna A, Artini M, Cavalli A, Levrero M, Bertoletti A, Pilli M, Chisari FV, Rehermann B, Del Prete G, Fiaccadori F, Ferrari C (1996) Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 98(5):1185–1194PubMedPubMedCentral
24.
Jung M-C, Pape GR (2002) Immunology of hepatitis B infection. Lancet 2(1):43–50PubMed
25.
Honorati M, Dolzani P, Mariani E, Piacentini A, Lisignoli G, Ferrari C, Facchini A (1997) Epitope specificity of Th0/Th2 CD4+ T-lymphocyte clones induced by vaccination with rHBsAg vaccine. Gastroenterology 112(6):2017–2027PubMed
26.
Desombere I, Willems A, Gijbels Y, Leroux-Roels G (2006) Partial delipidation improves the T-cell antigenicity of hepatitis B virus surface antigen. J Virol 80(7):3506–3514PubMedPubMedCentral
27.
Gomez-Gutierrez J, Rodriguez-Crespo I, Peterson D, Gavilanes F (1995) Antigenicity of hepatitis B surface antigen proteins reconstituted with phospholipids. Biochim Biophys Acta 1233:205–212PubMed
28.
Diminsky D, Moav M Gorecki, Barenholz Y (1999) Physical, chemical and immunological stability of CHO-derived hepatitis B surface antigen (HBsAg) particles. Vaccine 18:3–17PubMed
29.
Zhao Q, Wang Y, Freed D, Fu TM, Gimenez JA, Sitrin RD et al (2006) Maturation of recombinant hepatitis B virus surface antigen particles. Hum Vaccin 2:174–180PubMed
30.
Greiner V, Manin C, Larquet E, Ikhelef N, Gréco F, Naville S, Milhiet PE, Ronzon F, Klymchenko A, Mély Y (2014) Characterization of the structural modifications accompanying the loss of HBsAg particle immunogenicity. Vaccine 32:1049–1054PubMed
31.
Wu J, Lu M, Meng Z, Trippler M, Broering R, Szczeponek A et al (2007) Toll-like receptor-mediated control of HBV replication by nonparenchymal liver cells in mice. Hepatology 46:1769–1778PubMed
32.
Wu J, Meng Z, Jiang M et al (2009) Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. Hepatology 49:1132–1140PubMed
33.
Gray D, Gray M, Barr T (2007) Innate responses of B cells. Eur J Immunol 37(12):3304–3310PubMed
34.
Buynak EB, Roehm RR, Tytell AA, Bertland AU, Lampson GP, Hilleman MR (1976) Vaccine against human hepatitis B. JAMA 235(26):2832–2834PubMed
35.
Maupas P, Goudeau A, Coursaget P, Drucker J, Bagros P (1976) Immunisation against hepatitis B in man. Lancet 1(7974):1367–1370PubMed
36.
Zanetti AR, Van Damme P, Shouval D (2008) The global impact of vaccination against hepatitis B: a historical overview. Vaccine 26(49):6266–6273PubMed
37.
38.
Shoural D, Ilan Y, Adler R, Deepen R, Panet A, Even-Chen Z, Gorecki M, Gerlich WH (1994) Improved immunogenicity in mice of a mammalioan cell-derived recombinant hepatitis B vaccine containing pre-S1 and Pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine 12:1453–1459
39.
Shouval D, Roggendorf H, Roggendorf M (2015) Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1/Pre-S2/S vaccine. Med Microbiol Immunol 204:57–68PubMedPubMedCentral
40.
Hoa PT, Huy NT, le Thu T, Nga CN, Nakao K, Eguchi K, Chi NH, Hoang BH, Hirayama K (2009) Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B. Antimicrob Agents Chemother 53(12):5134–5140PubMedPubMedCentral
41.
Wang H, Han Q, Zhao H, Xu D, Zhang J (2018) Single dose HBsAg CS-γ-PGA nanogels induce potent protective immune responses against HBV infection. Eur J Pharm Biopharm 124:82–88PubMed
42.
Lim YT, Shim SM, Noh YW, Lee KS, Choi DY, Uyama H et al (2011) Bioderived polyelectrolyte nanogels for robust antigen loading and vaccine adjuvant effects. Small 7:3281–3286PubMed
43.
Lugade A, Bharali D, Pradhan V, Elkin G, Mousa S, Thanayala Y (2013) Single low-dose un-adjuvanted HBsAg nanoparticle vaccine elicits robust, durable immunity. Nanomedicine 9(7):923–934PubMed
44.
Leroux-Roels G, Van Belle P, Vandepapeliere P, Horsmans Y, Janssens M, Carletti I, Garçon N, Wettendorff M, Van Mechelen M (2015) Vaccine adjuvant systems containing monophosphoryl lipid A and QS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination. Vaccine 33(8):1084–1091PubMed
45.
Jesus S, Soares E, Borchard G, Borges O (2017) Poly-ϵ-caprolactone/chitosan nanoparticles provide strong adjuvant effect for hepatitis B antigen. Nanomedicine 12(19):2335–2348PubMed
46.
47.
Filippelli M, Lionetti E, Gennaro A, Lanzafame A, Arrigo T, Salpietro C et al (2014) Hepatitis B vaccine by intradermal route in non responder patients: an update. World J Gastroenterol 20(30):10383–10394PubMedPubMedCentral
48.
Zuckerman JN (2006) Protective efficacy, immunotherapeutic potential, and safety of hepatitis B vaccines. J Med Virol 78:169–177PubMed
49.
50.
Or Kalchiem-Dekel, Grupel D, Bouchnik L, Sikule E, Ben-Yakov G (2015) Efficacy and long-term durability of intradermal recombinant hepatitis B virus vaccine among intramuscular vaccine nonresponders: a prospective study in healthcare personnel. J Gastroenterol and Hepatol 30:1782–1787
51.
Fan W, Chen X, Shen C, Guo Z, Dong C (2016) Hepatitis B vaccine response in obesity: a meta-analysis. Vaccine 34(40):4835–4841PubMed
52.
53.
Schillie S, Murphy TV, Sawyer M et al (2013) CDC guidance for evaluating health-care personnel for hepatitis B virus protection and for administering post exposure management. MMWR Recomm Rep 62(RR-10):1–19PubMed
54.
Maltezou HC, Poland GA (2014) Vaccination policies for healthcare workers in Europe. Vaccine 32:4876–4880PubMed
55.
Lu CY, Ni YH, Chiang BL, Chen PJ, Chang MH, Chang LY et al (2008) Humoral and cellular immune responses to a hepatitis B vaccine booster 15–18 years after neonatal immunization. J Infect Dis 197:1419–1426PubMed
56.
Salama I, Sami S, Salama S, Rabah T, El Etreby L, Abdel Hamid A, Elmosalami D, El Hariri H, Said ZN (2016) Immune response to second vaccination series of hepatitis B virus among booster dose non-responders. Vaccine 34(16):1904–1908PubMed
57.
Valats J, Tuaillon E, Funakoshi N, Hoa D, Brabet MC, Bolloré K, Ducos J, Vendrell JP, Blanc P (2010) Investigation of memory B cell responses to hepatitis B surface antigen in health care workers considered as non-responders to vaccination. Vaccine 28(39):6411–6416PubMed
58.
Zaffina S, Marcellini V, Santoro AP, Scarsella M, Camisa V, Vinci MR, Musolino AM, Nicolosi L (2014) Repeated vaccinations do not improve specific immune defenses against hepatitis B in non-responder health care workers. Vaccine 32(51):6902–6910PubMed
59.
Weihrauch MR, von Bergwelt-Baildon M, Kandic M, Weskott M, Klamp W, Rosler J et al (2008) T cell responses to hepatitis B surface antigen are detectable in non-vaccinated individuals. World J Gastroenterol 14:2529–2533PubMedPubMedCentral
60.
Vingerhoets J, Vanham G, Kestens L, Penne G, Leroux-Roels G, Gigase P (1994) Deficient T-cell responses in non-responders to hepatitis B vaccination: absence of TH1 cytokine production. Immunol Lett 39:163–168PubMed
61.
Kardar GA, Jeddi-Tehrani M, Shokri F (2002) Diminished Th1 and Th2 cytokine production in healthy adult nonresponders to recombinant hepatitis B vaccine. Scand J Immunol 55:311–314PubMed
62.
Boot HJ, van der Waaij LA, Schirm J, Kallenberg CG, van Steenbergen J, Wolters B (2009) Acute hepatitis B in a healthcare worker: a case report of genuine vaccination failure. J Hepatol 50:426–431PubMed
63.
Heininger U, Gambon M, Gruber V, Margelli D (2010) Successful hepatitis B immunization in non- and low responding health care workers. Hum Vaccin 6(9):725–728
64.
CDC (2018) Prevention of hepatitis B virus infection in the United States: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep 67(No. RR-1)
65.
Greub G, Zysset F, Genton B, Spertini F, Frei PC (2001) Absence of anti-hepatitis B surface antibody after vaccination does not necessarily mean absence of immune response. Med Microbiol Immunol 189(3):165–168PubMed
66.
Heijtink RA, Schneeberger PM, Postma B, Crombach W (2002) Anti-HBs levels after hepatitis B immunisation depend on test reagents: routinely determined 10 and 100 IU/L seroprotection levels unreliable. Vaccine 20(23–24):2899–2905PubMed
67.
Ferguson M, Yu MW, Heath A (2010) Calibration of the second international standard for hepatitis B immunoglobulin in an international collaborative study. Vox Sang 99:77–84PubMed
68.
Raven S, Hautvast J, Steenbergen JV, Akkermans R, Weykamp C, Smits F, Hoebe C, Vossen A (2017) Diagnostic performance of serological assays for anti-HBs testing: results from a quality assessment program. J Clin Viroll 87:17–22
69.
Huzly D, Schenk T, Jilg W, Neumann-Haefelin D (2008) Comparison of nine commercially available assays for quantification of antibody response to hepatitis B virus surface antigen. J Clin Microbiol 46:1298–1306PubMedPubMedCentral
70.
Madiyal M, Sagar S, Vishwanath S, Banerjee B, Kalwaje V, Chawla K (2016) Comparing assay performance of elisa and chemiluminescence immunoassay in detecting antibodies to hepatitis B surface antigen. J Clin Diag Res 10(11):DC22–DC25
71.
Kinn S, Akhavan S, Agut H, Thibault V (2011) Performance of the DiaSorin LIAISON® anti-HBs II for the detection of hepatitis B surface antibodies: Comparison with the Abbott Architect anti-HBs assay. J Clin Virol 50:297–302PubMed
72.
Selby C (1999) Interference in immunoassay. Ann Clin Biochem 36:704–721PubMed
73.
Tuaillon E, Tabaa YA, Petitjean G, Huguet MF, Pajeaux G, Fondere JM, Ponseille B, Ducos J, Blanc P, Vendrell JP (2006) Detection of memory B lymphocytes specific to hepatitis B virus (HBV) surface antigen (HBsAg) from HBsAg-vaccinated or HBV-immunized subjects by ELISPOT assay. J Immunol Methods 315(1–2):144–152PubMed
74.
Bagheri-Jamebozorgi M, Keshavarz J, Nemati M, Mohammadi-Hossainabad S, Rezayati MT, Nejad-Ghaderi M, Jamalizadeh A, Shokri F, Jafarzadeh A (2014) The persistence of anti-HBs antibody and anamnestic response 20 years after primary vaccination with recombinant hepatitis B vaccine at infancy. Hum Vaccin Immunother 10(12):3731–3736PubMedPubMedCentral
75.
Brunskole Hummel I, Zitzmann A, Erl M, Wenzel JJ, Jilg W (2016) Characteristics of immune memory 10–15 years after primary hepatitis B vaccination. Vaccine 34(5):636–642PubMed
76.
Wang ZZ, Gao YH, Lu W, Jin CD, Zeng Y, Yan L, Ding F, Li T, Liu XE, Zhuang H (2017) Long-term persistence in protection and response to a hepatitis B vaccine booster among adolescents immunized in infancy in the western region of China. Hum Vaccin Immunother 13(4):909–915PubMed
77.
Dini G, Toletone A, Barberis I, Debarbieri N, Massa E, Paganino C, Bersi F, Montecucco A, Alicino C, Durando P (2017) Persistence of protective anti-HBs antibody levels and anamnestic response to HBV booster vaccination: a cross-sectional study among healthcare students 20 years following the universal immunization campaign in Italy. Hum Vaccin Immunother 13(2):440–444PubMed
78.
Banatvala J, Van-Damme P, Oehen S (2001) Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine 19:877–885
79.
Wang R-X, Boland G, Hattum J, de Gast GC (2004) Long term persistence of T cell memory to HBsAg after hepatitis B vaccination. World J Gastroenterol 10(2):260–263PubMedPubMedCentral
80.
Bocher B, Herzog-Hauff S, Herr W, Heermann K, Gerken G, Meyer Z, Lohr HF (1996) Regulation of the neutralizing anti-hepatitis B surface (HBs) antibody response in vitro in HBs vaccine recipients and patients with acute or chronic hepatitis B virus (HBV) infection. Clin Exp Immunol 105(1):52–58PubMedPubMedCentral
81.
Bauer T, Jilg W (2006) Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 24(5):572–577PubMed
82.
Bernasconi NL, Traggiai E, Lanzavecchia A (2002) Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298:2199–2202PubMed
83.
Gilca V, De Serres G, Boulianne N, Murphy D, De Wals P, Ouakki M et al (2013) Anti-body persistence and the effect of a booster dose given 5, 10 or 15 years aftervaccinating preadolescents with a recombinant hepatitis B vaccine. Vaccine 31:448–451PubMed
84.
Spada E, Romano L, Tosti ME, Zuccaro O, Paladini S, Chironna M et al (2014) Hepatitis B immunity in teenagers vaccinated as infants: an Italian 17-year follow-upstudy. Clin Microbiol Infect 20:O680–O686PubMed
85.
Salleras L, Dominguez A, Bruguera M, Plans P, Costa J, Cardenosa N et al (2007) Declining prevalence of hepatitis B virus infection in Catalonia (Spain) 12 years after the introduction of universal vaccination. Vaccine 25(52):8726–8731PubMed
86.
Campagna M, Siddu A, Meloni A, Murru C, Masia G, Coppola RC (2011) Epidemiological impact of mandatory vaccination against hepatitis B in Italian young adults. Hepat Mon 11(9):750–752PubMedPubMedCentral
87.
Coppola RC, Meloni A, Campagna M (2012) Impact of universal vaccination against hepatitis B: the italian model. Hepat Mon 12(7):417–419PubMedPubMedCentral
88.
89.
Poovorawan Y, Chongsrisawat V, Theamboonlers A, Leroux-Roels G, KuriyakoseS Leyssen M et al (2011) Evidence of protection against clinical and chronic hepatitisB infection 20 years after infant vaccination in a high endemicity region. J Viral Hepat 18:369–375PubMedPubMedCentral
90.
Sadlier C, Madden K, O’Gorman S, Crowley B, Bergin C (2017) Development of chronic hepatitis B infection in a hepatitis B vaccine responder. Int J STD AIDS 28(5):526–528PubMed
91.
92.
93.
Leuridan E, Van Damme P (2011) Hepatitis B and the need for a booster dose. Clin Infect Dis 53(1):68–75PubMed
94.
95.
WHO. Hepatitis B vaccines (2009) Releve epidemiologique hebdomadaire / Section d’hygiene du Secretariat de la Societe des Nations 5 Wkly Epidemiol Rec / Health Section of the Secretariat of the League of Nations 84:405–419
96.
Bachmann MF, Kündig TM, Oderman B, Hengartner H, Zinkernagel RM (1994) Free recirculation of memory B cells versus antigen-dependent differentiation to antibody forming cells. J Immunol 153:3386–3397PubMed
97.
Delves P, Roitt I (2000) The immune system (First of Two Parts). N Engl J Med 343:37–49PubMed
98.
99.
100.
Pawlotsky J-M (2005) The concept of hepatitis B virus mutant escape. J Clin Virol 34(Suppl 1):S125–S129PubMed
101.
Pondé RA (2013) Atypical serological profiles in hepatitis B virus infection. Eur J Clin Microbiol Infect Dis 32(4):461–476PubMed
102.
Ogura Y, Kurosaki M, Asahina Y, Enomoto N, Marumo F, Sato C (1999) Prevalence and significance of naturally occurring mutations in the surface and polymerase genes of hepatitis B virus. J Infect Dis 180:1444–1451PubMed
103.
Chongsrisawat V, Thawornsuk N, Theamboonlers A, Louisirirotchanakul S, Poovorawan Y (2006) Hepatitis B virus DNA in unusual serological profiles of hepatitis B surface antigen-positive sera. Viral Immunol 19(4):623–629PubMed
104.
Zhang JM, Xu Y, Wang XY, Yin YK, Wu XH, Weng XH, Lu M (2007) Coexistence of hepatitis B surface antigen (HBsAg) and heterologous subtype-specific antibodies to HBsAg among patients with chronic hepatitis B virus infection. Clin Infect Dis 44(9):1161–1169PubMed
105.
Zhang ZH, Li L, Zhao XP, Glebe D, Bremer CM, Zhang ZM, Tian YJ, Wang BJ, Yang Y, Gerlich W, Roggendorf M, Li X, Lu M, Yang DL (2011) Elimination of hepatitis B virus surface antigen and appearance of neutralizing antibodies in chronically infected patients without viral clearance. J Viral Hepat 18(6):424–433PubMed
106.
Pondé RA (2011) The underlying mechanisms for the “simultaneous HBsAg and anti-HBs serological profile”. Eur J Clin Microbiol Infect Dis 30(11):1325–1340PubMed
107.
Golsaz-Shirazi F, Mohammadi H, Amiri MM, Khoshnoodi J, Kardar GA, Jeddi-Tehrani M, Shokri F (2016) Localization of immunodominant epitopes within the “a” determinant of hepatitis B surface antigen using monoclonal antibodies. Arch Virol 161(10):2765–2772PubMed
108.
Tonekaboni SS, Waters J, Jeffers S, Gehrke R, Ofenloch B, Horsch A, Hess G, Howard C, Karayiannis P (2000) Effect of variation in the common ‘a’ determinant on the antigenicity of hepatitis B surface antigen. J Med Virol 60:113–121
109.
Servant-Delmas A, Mercier-Darty M, Ly TD, Wind F, Alloui C, Sureau C, Laperche S (2012) Variable capacity of 13 hepatitis B virus surface antigen assays for the detection of HBsAg mutants in blood samples. J Clin Virol 53(4):338–345PubMed
110.
Millman I, McMichael J (1978) Glycoproteins of natural origin with an affinity for hepatitis B surface antigen. Infect Immun 21(3):879–885PubMedPubMedCentral
111.
Solaas MH (1979) Discrimination of antibodies to hepatitis B surface antigen from antibodies to inherited serum protein variants in immune sera of human and animal origin. J Immunogenet 6(5):317–328PubMed
Metadaten
Titel
Expression and detection of anti-HBs antibodies after hepatitis B virus infection or vaccination in the context of protective immunity
verfasst von
Robério Amorim de Almeida Pondé
Publikationsdatum
09.08.2019
Verlag
Springer Vienna
Erschienen in
Archives of Virology / Ausgabe 11/2019
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI
https://doi.org/10.1007/s00705-019-04369-9

Weitere Artikel der Ausgabe 11/2019

Archives of Virology 11/2019 Zur Ausgabe

Original Article

Interferon gamma inhibits transmissible gastroenteritis virus infection mediated by an IRF1 signaling pathway

Brief Report

Molecular evidence of goose-parvovirus-related abnormal molting in Pekin ducks

Annotated Sequence Record

Complete genome sequence of a novel reassortant H3N3 avian influenza virus

Original Article

High-frequency mutation and recombination are responsible for the emergence of novel porcine reproductive and respiratory syndrome virus in northwest China

Brief Report

Sequence analysis of the medium and small RNAs of impatiens necrotic spot virus reveals segment reassortment but not recombination

Original Article

Bovine coronavirus in Uruguay: genetic diversity, risk factors and transboundary introductions from neighboring countries

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Metformin rückt in den Hintergrund

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Myokarditis nach Infekt – richtig schwierig wird es bei Profisportlern

24.04.2024 | DGIM 2024 | Kongressbericht | Nachrichten

Thrombophiliescreening – Wenn, dann richtig und nur bei therapeutischer Konsequenz

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise